Delving into the Latest Updates on Dexibuprofen with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

(+)-(S)-p-isobutylhydratropic acid, (2S)-2-(4-isobutylphenyl)propanoic acid, (S)-α-methyl-4-(2-methylpropyl)benzeneacetic acid

+ [19]

Target

COXs

Action

inhibitors

Mechanism

COX inhibitors(Cyclooxygenases inhibitors)

Therapeutic Areas

Immune System DiseasesNervous System DiseasesSkin and Musculoskeletal Diseases+ [1]

Active Indication

InflammationHeadacheBack Pain+ [8]

Inactive Indication

Acute PainAnesthesiaMyalgia

Originator Organization-

Active Organization

Zhongshan Union Weihua Pharmaceutical Co. Ltd.

Gebro Pharma GmbH

Overseas Pharmaceuticals Ltd.

+ [2]

Inactive Organization

Aponia Laboratories, Inc.

Drug Highest PhaseApproved

First Approval Date

Switzerland (28 Apr 1998),

Rheumatic Diseases

RegulationPriority Review (China)

Login to view timeline

Structure/Sequence

Molecular FormulaC13H18O2

InChIKeyHEFNNWSXXWATRW-JTQLQIEISA-N

CAS Registry51146-56-6

The main purpose of the study is to evaluate the pharmacokinetic differences between JC002 and the control formulation in the postprandial state and the effect of a high-fat meal on pharmacokinetics. The secondary purpose of the study is to study the safety of the test formulation and the control formulation in healthy adult subjects.

Start Date24 Jul 2024

Sponsor / Collaborator

Beijing Jiacheng Biomedical Technology Development Co., Ltd

100 Clinical Results associated with Dexibuprofen

Login to view more data

100 Translational Medicine associated with Dexibuprofen

Login to view more data

100 Patents (Medical) associated with Dexibuprofen

Login to view more data

1,912

Literatures (Medical) associated with Dexibuprofen

01 Mar 2025·Clinical Pharmacology in Drug Development

Antipyretic Effect of Dexibuprofen Versus Ibuprofen in Children With Fever Caused by Upper Respiratory Tract Infection

Article

Author: Cheng, Huanji ; Xie, Juanjuan ; Li, Changchong ; Wang, Xinli ; Zhao, Chengsong ; Shen, Kunling ; Zhao, Lin

AbstractDexibuprofen is the pharmacologically active enantiomer of ibuprofen. However, its application as an antipyretic in children with fever caused by upper respiratory tract infection (URTI) requires more evidence. This study aimed to compare the antipyretic effect between dexibuprofen and ibuprofen in children with fever caused by URTI. Totally, 281 subjects were randomly assigned to the dexibuprofen (N = 142) or ibuprofen (N = 139) group at a 1:1 ratio. The subjects in the dexibuprofen or ibuprofen group were administered dexibuprofen + ibuprofen mimetic solution or ibuprofen + dexibuprofen mimetic solution 1‐4 times per day. Dexibuprofen was considered at least as effective as ibuprofen if the lower limit of the 95% confidence interval (CI) for the mean difference in axillary temperature change at 4 hours was greater than −0.3°C. The axillary temperature change after 4 hours was 1.3°C in the dexibuprofen group and 1.4°C in the ibuprofen group. The difference in axillary temperature change at 4 hours was −0.10°C (95% CI, −0.27 to 0.09°C) between the 2 groups, and the lower limit of the 95% CI was greater than −0.3°C, suggesting a comparable antipyretic effect of dexibuprofen to ibuprofen. The axillary temperature change from baseline, rates of normal axillary temperature at 4 hours, time to normal axillary temperature, and disease‐related symptoms at 24 or 48 hours were not different between the dexibuprofen and ibuprofen groups (all P > .05). The incidence of adverse events did not differ between the 2 groups (all P > .05). In conclusion, dexibuprofen has a comparable antipyretic effect and safety profile to ibuprofen in Chinese children with fever caused by URTI.

01 Mar 2025·Colloids and Surfaces B: Biointerfaces

Dexibuprofen loaded into nanoemulsion based gel for topical application – In vitro characterization and in vivo anti-inflammatory evaluation

Article

Author: Khalid, Ikrima ; Munir, Muhammad Rehan ; Alshammari, Abdulrahman ; Munir, Rabia ; Kamal, Yousaf ; Khan, Ikram Ullah ; Albekairi, Norah A ; Asghar, Sajid ; Irfan, Muhammad ; Shah, Pervaiz Akhtar ; Asif, Muhammad ; Khalid, Syed Haroon

Arthritic disease is one of the most common diseases in adults and a leading cause of joint degeneration. Dexibuprofen (DEX) is routinely used for the treatment of rheumatoid arthritis, acute postoperative pain, primary dysmenorrheal, and in lower back pain. However, it is poorly water soluble with compromised bioavailability, and hence has limited therapeutic activity. In order to overcome these issues, we studied the formulation and characterization of nanoemulsion based system i.e nanoemulgel of DEX. This study aimed to prepare topical nanoemulgel containing 2 % DEX and solubility-enhanced DEX via ternary inclusion complexation (DEX-SE-T) and to compare it with commercially available 5 % Ibuprofen gel as there is no topical formulation of DEX is available in the market currently. A pseudoternary phase diagram was constructed using the spontaneous water titration method. Blank and drug-loaded nanoemulgel were prepared using a high-speed homogenization method. All the formulations were evaluated in terms of particle size, pH, conductivity, viscosity, zeta potential, and ex vivo drug permeation. DEX loaded nanoemulgel yield enhanced in vitro skin permeation than the commercially available 5 % ibuprofen gel. The optimized nanoemulgel formulation (DEX-SE-T) was tested in in vivo anti-inflammatory models including cotton pellets-induced abdominal granuloma (chronic inflammation) and carrageenan-induced paw edema (acute inflammation). DEX-SE-T loaded nanoemulgel has improved in vivo anti-inflammatory activity as compared to ibuprofen gel. DEX-SE-T could be a promising option for effective topical treatment of inflammatory conditions.

04 Feb 2025·Advanced Synthesis & Catalysis

Photocatalytic Silylation of Aryl Alkynoates: Synthesis of Silylated Coumarins

Author: Selvakumar, Sermadurai ; Samanta, Sourav ; Ladumor, Ravikumar

AbstractHerein, we report the photocatalytic synthesis of 3‐silyl coumarins using hydrosilanes as the silyl radical source with aryl alkynoates. Readily prepared N‐aminopyridinium salts act as hydrogen atom transfer reagents for generating silyl radicals under photoredox catalysis. The reaction proceeds through a silyl radical addition to alkyne followed by radical cascade cyclization/migration with subsequent oxidation and aromatization to give the desired 3‐silyl coumarins in 34–89% yield.

100 Deals associated with Dexibuprofen

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D03715	Dexibuprofen	M01AE14	DB09213

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Inflammation	South Korea	Gebro Pharma GmbH	31 Dec 2007
Headache	Argentina	-	16 Apr 2007
Back Pain	Argentina	-	02 Apr 2007
Musculoskeletal Pain	Argentina	-	01 Apr 2007
Dysmenorrhea	United Kingdom	-	14 Mar 2007
Fever	China	Hubei Biocause Heilen Pharmaceutical Co., Ltd.	01 Jan 2001
Osteoarthritis	China	-	01 Jan 2001
Rheumatoid Arthritis	China	-	01 Jan 2001
Pain	Switzerland	-	21 May 1998
Rheumatic Diseases	Switzerland	-	28 Apr 1998

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Anesthesia	Phase 3	China	Beijing Join Chain Medicine Co., Ltd.	16 Nov 2020
Anesthesia	Phase 3	China	Zhongshan Union Weihua Pharmaceutical Co. Ltd.	16 Nov 2020
Acute Pain	Phase 3	United States	Aponia Laboratories, Inc.	12 Jan 2018
Myalgia	Phase 3	United States	Aponia Laboratories, Inc.	01 Jan 2015
Analgesia	Phase 2	China	Beijing Join Chain Medicine Co., Ltd.	13 Jul 2021
Analgesia	Phase 2	China	Zhongshan Union Weihua Pharmaceutical Co. Ltd.	13 Jul 2021
Fever	Phase 2	China	Zhongshan Union Weihua Pharmaceutical Co. Ltd.	13 Jul 2021
Fever	Phase 2	China	Beijing Join Chain Medicine Co., Ltd.	13 Jul 2021
Dysmenorrhea	Phase 1	China	Overseas Pharmaceuticals Ltd.	17 May 2023
Osteoarthritis	Phase 1	China	Overseas Pharmaceuticals Ltd.	17 May 2023

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03852459 (CTgov)	Phase 2	Acute Pain \| Myalgia	251	S-Ibuprofen (Active Arm)	qmxmrjxelz(eefnovfjdd) = rlprkvycuu btenxopuxa (lqkzuspxei, lvxkiiqath - kvvlzggkpk) View more	-	25 Jan 2022
				Vehicle (Placebo Arm)	qmxmrjxelz(eefnovfjdd) = fglwahenjr btenxopuxa (lqkzuspxei, ogxqzrkkjd - jmpvlvhpzh) View more